在欧盟批准并进行第三阶段试验后,中国批准接受抗逆转录病毒药物治疗的Dupixent。 China approves Dupixent® for COPD treatment, following EU approval and Phase 3 trials.

中国已核准Dupixent(杜皮鲁马)为首例慢性阻塞性肺病生物治疗,其血液活性细胞素含量较高。 China has approved Dupixent® (dupilumab) as the first biologic treatment for chronic obstructive pulmonary disease (COPD) with elevated blood eosinophils. 这在欧盟批准后进行,并得到第三阶段试验的支持,这些试验在减少恶化、改善肺功能和生活质量方面大有裨益。 This follows its approval in the EU and is supported by Phase 3 trials showing significant benefits in reducing exacerbations and improving lung function and quality of life. 由于青蒿素综合症在中国非常普遍,这一批准符合中国2030年健康中国公共卫生倡议。 As COPD is highly prevalent in China, this approval aligns with the nation's Healthy China 2030 public health initiative.